SCHEMBL5555801

SCHEMBL5555801

N#Cc1ncc(Nc2ccc(-c3ccccc3)cc2)c2cc(C(=O)O)sc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 7/20 0.59
SLC22A12 Q96S37 1/20 0.39
GSK3B P49841 3/20 0.39
CSNK1D P48730 2/20 0.39
PIM1 P11309 2/20 0.39
PRKACA P17612 2/20 0.39
MAPK9 P45984 2/20 0.39
GSK3A P49840 2/20 0.39
RPS6KA3 P51812 2/20 0.39
AURKB Q96GD4 2/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
CHEK2 O96017 1/20 0.39
CDK1 P06493 1/20 0.39
CDK2 P24941 1/20 0.39
CSNK2A1 P68400 1/20 0.39
DYRK1A Q13627 1/20 0.39
PLK3 Q9H4B4 1/20 0.39
SGK2 Q9HBY8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5550728 0.92 MAP3K8 (0.50) MAP3K8GSK3BCSNK1DGSK3AAURKB
SCHEMBL5550740 0.83 MAP3K8 (0.63) MAP3K8GSK3BCSNK1DPIM1PRKACA
SCHEMBL5554216 0.81 MAP3K8 (0.60) MAP3K8GSK3BCSNK1DPIM1PRKACA
SCHEMBL5553889 0.76 MAP3K8 (0.65) MAP3K8GSK3BCSNK1DPIM1PRKACA
SCHEMBL5553787 0.76 MAP3K8 (0.65) MAP3K8GSK3BCSNK1DPIM1PRKACA
SCHEMBL5550172 0.75 MAP3K8 (0.53) MAP3K8GSK3BCSNK1DPIM1PRKACA
SCHEMBL5550805 0.75 MAP3K8 (0.53) MAP3K8GSK3BCSNK1DGSK3AAURKB
SCHEMBL5553894 0.75 MAP3K8 (0.64) MAP3K8GSK3BCSNK1DPIM1PRKACA
SCHEMBL5550658 0.75 MAP3K8 (0.64) MAP3K8GSK3BCSNK1DPIM1PRKACA
SCHEMBL5550648 0.75 MAP3K8 (1.00) MAP3K8GSK3BCSNK1DPIM1PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 MAP3K8 13/4885SLC22A12 3853/4885GSK3B 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.